Shares of Mind Medicine (MindMed) Inc. (MNMD) are soaring 5.38% in pre-market trading on Monday, following a positive analyst report from Evercore ISI. The surge comes as investors react to the reiterated Buy rating and the ambitious price target set for the psychedelic medicine company.

Evercore ISI analyst maintained their bullish stance on Mind Medicine, setting a price target of $23.00 for the stock. This vote of confidence from a respected Wall Street firm has evidently sparked renewed interest in MNMD shares. The price target suggests significant upside potential, which is likely contributing to the stock's strong performance in early trading.

Mind Medicine, a company at the forefront of developing psychedelic-inspired medicines and therapies, has been attracting attention in the biotechnology sector. The positive analyst coverage comes at a time when there's growing interest in alternative treatments for mental health conditions. As the market opens, investors will be watching closely to see if MNMD can maintain its momentum throughout the trading session.